Clean Science
Clean Science Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales. EBITDA margins are expected to improve over the next 2-3 years due to increased sales of higher-grade HALS and operational efficiencies.
From Clean Science's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales.
- HALS volume for the year is targeted above 3,000 metric tons, with consistent scale-up expected over next 2-3 years.
- EBITDA margins for HALS are projected to improve due to higher-grade product mix and operational efficiencies.
- Performance Chemical 2 plant commercialization expected by Q3 FY27, with revenues anticipated from Q1 FY28 after stabilization.
- Strategic collaborations (Geneus Chem, Kemin) expected to enhance revenue streams, including an incremental INR 300 crores over 4 years from Geneus tie-up.
- Export markets, especially the U.S. and Europe (via Netherlands subsidiary operational from mid-September), will support growth.
- Supply chain stability and raw material availability are key targets for ensuring steady production and revenue ramp-up.
Profitability & Margins
See what Clean Science said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 100 crores capex invested in subsidiary Clean Fino Chem Limited; all future products and new lines to be developed here.
- Geneus Chem tie-up involves a capex of about INR 25 crores for a new plant to produce advanced HALS products, expected to start production in Q3 FY27.
- Additional capacity expansion is planned to meet increased demand from Kemin contract; the process has already started.
- Performance Chemical 2 plant commercialization expected by Q3 FY27 (November-ish), with stabilization continuing till Q1 FY28.
- No detailed annual capex run rate provided yet; working on future plans and will update in due course.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Clean Science said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders in quantitative detail.
- However, Siddharth Sikchi stated that exports to the U.S. have been very steady despite tariff and China competition issues, indicating ongoing strong demand.
- A strategic 5-year contract with Kemin ensures assured volumes for certain key products, implying a secured portion of the order book with a significant global customer.
- The HALS business is expected to grow, with a revenue target of INR 250-300 crores for FY27, showing increasing order flow.
- The Geneus tie-up targets cumulative revenues of around INR 300 crores over four years, indicating ongoing and future order commitments.
- The Performance Chemicals 2 plant's commercialization is expected around November, with revenue ramp-up anticipated from Q1 FY28.
- No specific pending order numbers were given, but indications suggest a healthy and growing order pipeline aligned with capacity expansions.
Clean Science — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹249 Cr, net profit ₹58 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Clean Science & Technology Ltd's management said in earlier quarters
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Clean Science Q1 FY27 results?
HALS business revenue is expected to grow to INR 250-300 crores annually, contributing around 30-35% of overall revenue growth in FY27, with export constituting nearly 50% of HALS sales. EBITDA margins are expected to improve over the next 2-3 years due to increased sales of higher-grade HALS and operational efficiencies.
What is Clean Science share price analysis?
Clean Science currently shows a below-average growth signal. The stock trades at a P/E of 37.7 with a market cap of ₹8,774 Cr. Investors should review the full earnings analysis for detailed insights.
Is Clean Science planning capital expenditure?
INR 100 crores capex invested in subsidiary Clean Fino Chem Limited; all future products and new lines to be developed here.
Keep Clean Science on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.